A commentary in Journal of Cancer Research and Clinical Oncology challenged prior conclusions from an in silico lung adenocarcinoma study by emphasizing that docking scores do not prove binding affinity or therapeutic efficacy. The critique specifically questioned claims about interpreting TTK inhibition and the proposed role of hesperidin, noting the absence of enzymatic, cellular, or in vivo functional validation tied to TTK target engagement. For the pipeline ecosystem, the piece is a reminder that computational findings still require wet-lab confirmation—especially when treated as mechanistic proof for specific natural-product candidates.
Get the Daily Brief